M E Cudkowicz

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis
    M E Cudkowicz
    Day Neuromuscular Research Laboratory, Massachusetts General Hospital, Charlestown 02114, USA
    Neurology 52:1492-4. 1999
  2. ncbi request reprint Functional outcome measures as clinical trial endpoints in ALS
    B J Traynor
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurology 63:1933-5. 2004
  3. doi request reprint Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS
    A M Wills
    Day Neuromuscular Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Neurology 70:929-34. 2008
  4. ncbi request reprint A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
    M E Cudkowicz
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neurology 61:456-64. 2003
  5. ncbi request reprint Neuroprotective agents for clinical trials in ALS: a systematic assessment
    B J Traynor
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, USA
    Neurology 67:20-7. 2006
  6. ncbi request reprint Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity
    M E Cudkowicz
    Day Neuromuscular Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurology 59:729-34. 2002
  7. ncbi request reprint Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis
    H D Rosas
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Neurology 60:1615-20. 2003

Detail Information

Publications7

  1. ncbi request reprint The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis
    M E Cudkowicz
    Day Neuromuscular Research Laboratory, Massachusetts General Hospital, Charlestown 02114, USA
    Neurology 52:1492-4. 1999
    ..We found that oral administration of Procysteine was safe. Procysteine enters CSF after both IV and oral dosing and accumulates to significant levels in CSF. We also observed that CSF levels of glutathione fall dramatically with aging...
  2. ncbi request reprint Functional outcome measures as clinical trial endpoints in ALS
    B J Traynor
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurology 63:1933-5. 2004
    ..Rates of FVC% and ALFRS decline, but not of MVIC-arm or MVIC-grip, were independent predictors of survival...
  3. doi request reprint Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS
    A M Wills
    Day Neuromuscular Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Neurology 70:929-34. 2008
    ..We tested the hypothesis that this association correlates with functional changes in paraoxonase 1 (PON1, MIM 168820)...
  4. ncbi request reprint A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
    M E Cudkowicz
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neurology 61:456-64. 2003
    ..To determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS...
  5. ncbi request reprint Neuroprotective agents for clinical trials in ALS: a systematic assessment
    B J Traynor
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, USA
    Neurology 67:20-7. 2006
    ..Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest...
  6. ncbi request reprint Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity
    M E Cudkowicz
    Day Neuromuscular Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurology 59:729-34. 2002
    ..To test this hypothesis, the authors generated transgenic ALS mice with altered levels of glutathione peroxidase (GSHPx), the major soluble enzyme that detoxifies H2O2...
  7. ncbi request reprint Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis
    H D Rosas
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Neurology 60:1615-20. 2003
    ....